Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.

Detailed Description
-----------------
In this study, a mitochondria-specific antioxidant will be compared to a placebo. Participants will be assigned randomly to receive either the antioxidant or the placebo for 6 weeks. A comprehensive assessment of cardiovascular health will be conducted before and after the administration of the supplement.

Official Title
-----------------
The Influence of Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Dietary Supplement: MitoQ
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically diagnosed of COPD Global Initiative for obstructive lung disease (GOLD) Stages II to IV Exclusion Criteria: Forced Expiratory Volume in 1 second/ Functional Vital Capacity (FEV1/FVC) >0.7 Heart Disease Diabetes Vasoactive medications Uncontrolled high blood pressure Fluid in lungs Sleep apnea Raynaud's Phenomenon Gangrene of the digits History of coagulation Pregnant women Children

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MitoQ<br>Participants will take 1 pill each day for 6 weeks | Dietary Supplement: MitoQ<br>* MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.<br>|
| Placebo Comparator: Placebo<br>Participants will take 1 pill each day for 6 weeks | Other: Placebo<br>* A look-alike inactive substance, a sugar pill<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in vascular function | Flow-mediated dilation will be used to measure vasodilation in the brachial artery | Baseline and 6 weeks | 
| Change in Skeletal Muscle Oxygenation | Near-infrared spectroscopy will be used to measure leg muscle oxygenation | Baseline and 6 weeks | 
| Change in oxidative stress | Blood draws will be taken to measure oxidative stress markers in the blood through electron paramagnetic resonance | Baseline and 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in arterial stiffness | Pulse wave velocity will be used to measure arterial stiffness. | Baseline and 6 weeks | 
| Change in microvascular function | Microvascular function will be assessed using laser dopler imaging | Baseline and 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MitoQ, vascular function, cardiovascular health, exercise intolerance, Mitochondria